RxDoctor Payments Data

Benjamin Raucher

Family · Catonsville, MDNPI 1578276689

Payments from drug & device makers

$2,837in general payments, 2019–2025

Across 116 payments — averaging $24.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$539
  • Novo Nordisk$512
  • Astellas Pharma US Inc$438
  • Exact Sciences$211
  • Merck$191
  • Lilly USA, LLC$163
  • plus $783 from 14 others

What the payments were for

  • Food & beverage$2,837100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,837 in reported general payments places this provider in the 85th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$57,971
Medicare patients
256
Services billed
918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$37,693
EliquisApixaban33$37,223
JardianceEmpagliflozin32$22,584
TrulicityDulaglutide12$11,539
FarxigaDapagliflozin Propanediol11$9,490
Atorvastatin Calcium186$3,805
Amlodipine Besylate192$3,062
Albuterol Sulfate HfaAlbuterol Sulfate91$2,142
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,676
Losartan Potassium57$1,250
Metoprolol Succinate61$1,229
Pravastatin Sodium43$990
Nifedipine ErNifedipine28$851
Metformin Hcl67$850
Lisinopril74$831

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$512$37,69333 claims
PfizerEliquis$113$37,22333 claims
Lilly USA, LLCTrulicity$163$11,53912 claims
AstraZenecaFarxiga$539$9,49011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,843 family providers in Maryland.

Other family in Catonsville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →